EMA follows FDA to approve Roche's Tecentriq combo for frontline use in triple negative breast cancer
Months after Roche secured US approval for its checkpoint inhibitor Tecentriq, in combination with Celgene’s Abraxane, for frontline use in an aggressive, tough-to-treat subgroup of breast cancer patients — the EU has followed suit.
On Thursday, the Swiss giant said the Tecentriq combo is the first cancer immunotherapy regimen to be cleared by European regulators for triple-negative breast cancer (TNBC).
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.